OXFORD BIOMEDICA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 331 GBX | +3.28% |
|
+1.22% | +50.45% |
| May. 09 | Avon Protection wins UK MoD supply deal; Molten Ventures up | AN |
| May. 09 | Molten Ventures wins UK MoD supply contract | AN |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 467.4 | 495.7 | 847.6 | 1,059 | 426 | 331 | 331 | - |
| Enterprise Value (EV) 1 | 476.3 | 487.8 | 814.5 | 950.4 | 324.5 | 213 | 312.7 | 316.1 |
| P/E ratio | 64.9 x | -29.2 x | -132 x | 55.4 x | -10.7 x | -1.35 x | -9.44 x | -28.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 7 x | 7.74 x | 9.66 x | 7.42 x | 3.04 x | 2.38 x | 2.56 x | 2.01 x |
| EV / Revenue | 7.13 x | 7.61 x | 9.28 x | 6.66 x | 2.32 x | 2.38 x | 2.42 x | 1.92 x |
| EV / EBITDA | 35.5 x | -93.8 x | 112 x | 26.5 x | 203 x | -4.03 x | -35.9 x | 16.4 x |
| EV / FCF | 172 x | -16.7 x | -79.5 x | 59.4 x | -11.2 x | -5.66 x | -14.4 x | 304 x |
| FCF Yield | 0.58% | -6% | -1.26% | 1.68% | -8.91% | -17.7% | -6.97% | 0.33% |
| Price to Book | - | - | 7.3 x | 5.48 x | 2.08 x | 2.15 x | 5.74 x | 9.01 x |
| Nbr of stocks (in thousands) | 66,089 | 76,848 | 82,294 | 86,126 | 96,263 | 100,000 | 100,000 | - |
| Reference price 2 | 7.072 | 6.450 | 10.30 | 12.30 | 4.425 | 3.310 | 3.310 | 3.310 |
| Announcement Date | 3/14/19 | 5/6/20 | 4/15/21 | 4/20/22 | 4/25/23 | 4/29/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 66.78 | 64.06 | 87.73 | 142.8 | 140 | 89.54 | 129.3 | 164.9 |
| EBITDA 1 | 13.4 | -5.2 | 7.3 | 35.9 | 1.6 | -52.8 | -8.699 | 19.29 |
| EBIT 1 | 13.92 | -14.47 | -5.694 | 20.77 | -30.22 | -184.2 | -36.07 | -16.12 |
| Operating Margin | 20.84% | -22.58% | -6.49% | 14.54% | -21.59% | -205.69% | -27.89% | -9.78% |
| Earnings before Tax (EBT) 1 | 5.014 | -20.89 | -6.572 | 19.88 | -45.98 | -188.5 | -40.12 | -17.09 |
| Net income 1 | 7.541 | -16.07 | -6.245 | 19.01 | -39.16 | -157.5 | -36.47 | -12.48 |
| Net margin | 11.29% | -25.08% | -7.12% | 13.31% | -27.97% | -175.89% | -28.2% | -7.57% |
| EPS 2 | 0.1089 | -0.2210 | -0.0781 | 0.2220 | -0.4129 | -1.631 | -0.3508 | -0.1173 |
| Free Cash Flow 1 | 2.765 | -29.28 | -10.24 | 15.99 | -28.91 | -49.79 | -21.78 | 1.04 |
| FCF margin | 4.14% | -45.71% | -11.67% | 11.2% | -20.65% | -55.03% | -16.84% | 0.63% |
| FCF Conversion (EBITDA) | 20.63% | - | - | 44.55% | - | - | - | 5.39% |
| FCF Conversion (Net income) | 36.67% | - | - | 84.13% | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/14/19 | 5/6/20 | 4/15/21 | 4/20/22 | 4/25/23 | 4/29/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 32.1 | 31.96 | 33.98 | 53.75 | 81.25 | 61.54 | 64.03 | 75.96 | 43.06 | 46.48 | 53.3 | 76.7 |
| EBITDA | -1.41 | -3.79 | -0.398 | 7.7 | 27.09 | 8.808 | -5.785 | 7.385 | -33.73 | -19.1 | - | - |
| EBIT 1 | -4.895 | -9.572 | -5.766 | 0.072 | 19.66 | 1.11 | -19.16 | -11.06 | -50.75 | -133.4 | -17.1 | -7.8 |
| Operating Margin | -15.25% | -29.95% | -16.97% | 0.13% | 24.19% | 1.8% | -29.92% | -14.56% | -117.85% | -287.07% | -32.08% | -10.17% |
| Earnings before Tax (EBT) 1 | -12.11 | -8.776 | -6.126 | -0.446 | 19.22 | 0.663 | -27.38 | -18.59 | -52.34 | -136.2 | -18.6 | -9.3 |
| Net income 1 | -10.17 | -5.898 | -6.679 | 0.434 | 18.07 | 0.942 | -25.48 | -13.67 | -47.96 | -152.8 | -18.6 | -4.9 |
| Net margin | -31.68% | -18.45% | -19.66% | 0.81% | 22.24% | 1.53% | -39.8% | -18% | -111.37% | -328.73% | -34.9% | -6.39% |
| EPS 2 | -0.1483 | -0.0727 | -0.0869 | 0.008800 | 0.2136 | 0.008400 | -0.2729 | -0.1400 | -0.4974 | -1.134 | -0.1467 | -0.0262 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 9/4/19 | 5/6/20 | 9/17/20 | 4/15/21 | 9/22/21 | 4/20/22 | 9/15/22 | 4/25/23 | 9/20/23 | 4/29/24 | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 8.91 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 7.85 | 33.1 | 109 | 102 | 49.2 | 18.3 | 14.9 |
| Leverage (Debt/EBITDA) | 0.6649 x | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 2.77 | -29.3 | -10.2 | 16 | -28.9 | -49.8 | -21.8 | 1.04 |
| ROE (net income / shareholders' equity) | - | - | -6.63% | 12.7% | -20% | -49.9% | -60.9% | -38.7% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | -21.5% | -14.5% | -9.92% |
| Assets 1 | - | - | - | - | - | 415.5 | 250.9 | 125.8 |
| Book Value Per Share 2 | - | - | 1.410 | 2.240 | 2.130 | 1.540 | 0.5800 | 0.3700 |
| Cash Flow per Share 2 | 0.1900 | -0.0500 | 0.0400 | 0.3000 | -0.1300 | -0.5000 | -0.4500 | 0.0600 |
| Capex 1 | 10.1 | 25.8 | 13.4 | 9.46 | 16.3 | 10.9 | 12.9 | 11.7 |
| Capex / Sales | 15.13% | 40.23% | 15.23% | 6.63% | 11.64% | 12.01% | 9.96% | 7.09% |
| Announcement Date | 3/14/19 | 5/6/20 | 4/15/21 | 4/20/22 | 4/25/23 | 4/29/24 | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.31
GBP
Average target price
4.489
GBP
Spread / Average Target
+35.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +50.45% | 408M | |
| +11.91% | 114B | |
| +11.60% | 105B | |
| -4.68% | 23.83B | |
| -0.82% | 21.73B | |
| -10.12% | 18.1B | |
| -42.12% | 16.34B | |
| -17.47% | 16.13B | |
| +2.77% | 13.75B | |
| +34.58% | 11.76B |
- Stock Market
- Equities
- OXB Stock
- Financials Oxford Biomedica plc
